Rechallenge With 177 Lu-PSMA Radioligand Therapy in Metastatic Castration-resistant and Hormone-sensitive Prostate Cancer : Lessons From a Multicase Experience.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 42544985.
- Also identified by DOI 10.1097/RLU.0000000000006490.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We report 4 patients with metastatic hormone-sensitive (mHSPC) or castration-resistant prostate cancer (mCRPC) treated with 177 Lu-PSMA-617 radioligand therapy (RLT), including rechallenge after disease progression. Initial RLT induced significant PSA declines, pain relief, and radiographic responses. Upon biochemical or clinical progression, rechallenge with additional 177 Lu-PSMA cycles achieved renewed PSA reductions, sustained symptomatic improvement, and favorable safety, with no grade III-IV hematologic or renal toxicities. These cases illustrate the dynamic application of 177 Lu-PSMA across disease stages and suggest that prior exposure does not preclude subsequent retreatment, supporting the feasibility and efficacy of RLT rechallenge in both mCRPC and mHSPC settings.
Medical subject headings
- Prostatic Neoplasms, Castration-Resistant
- Dipeptides
- Lutetium
- Heterocyclic Compounds
- Heterocyclic Compounds, 1-Ring